Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells $86,000.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $10.75, for a total value of $86,000.00. Following the completion of the sale, the chief operating officer now directly owns 639,982 shares in the company, valued at approximately $6,879,806.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tina Marriott also recently made the following trade(s):

• On Thursday, February 22nd, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $14.89, for a total value of $119,120.00.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $10.17 on Thursday. The stock’s 50-day moving average is $11.16 and its 200-day moving average is $9.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.54 and a 12 month high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. The company had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Recursion Pharmaceuticals by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company’s stock valued at $154,459,000 after buying an additional 158,376 shares during the period. Mubadala Investment Co PJSC purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $128,041,000. Goldman Sachs Group Inc. raised its holdings in shares of Recursion Pharmaceuticals by 79.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,191,805 shares of the company’s stock valued at $11,751,000 after buying an additional 527,032 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Recursion Pharmaceuticals by 6.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 56,564 shares of the company’s stock valued at $558,000 after buying an additional 3,589 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at approximately $107,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RXRX. Needham & Company LLC increased their price objective on Recursion Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. TD Cowen initiated coverage on Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a “market perform” rating on the stock. Finally, KeyCorp increased their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $12.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.